Federated Hermes
ADMA icon

Federated Hermes’s ADMA Biologics ADMA Stock Holding History

Federated Hermes’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.49M Sell
1,014,817
-686,498
-40% -$6.26M 0.01% 734
2026
Q1 		$15.3M Buy
1,701,315
+1,511,656
+797% +$23.9M 0.02% 534
2025
Q4 		$3.46M Sell
189,659
-331,394
-64% -$5.59M 0.01% 857
2025
Q3 		$7.64M Sell
521,053
-415,928
-44% -$7.13M 0.01% 632
2025
Q2 		$17.1M Sell
936,981
-267,146
-22% -$5.45M 0.03% 462
2025
Q1 		$23.9M Sell
1,204,127
-102,809
-8% -$1.78M 0.05% 369
2024
Q4 		$22.4M Sell
1,306,936
-320,757
-20% -$6.03M 0.05% 388
2024
Q3 		$32.5M Sell
1,627,693
-342,118
-17% -$5.32M 0.07% 321
2024
Q2 		$22M Buy
1,969,811
+263,677
+15% +$2.21M 0.05% 385
2024
Q1 		$11.3M Buy
1,706,134
+899,122
+111% +$4.91M 0.03% 543
2023
Q4 		$3.65M Buy
807,012
+33,767
+4% +$125K 0.01% 796
2023
Q3 		$2.77M Buy
773,245
+111,631
+17% +$430K 0.01% 837
2023
Q2 		$2.44M Sell
661,614
-250,348
-27% -$928K 0.01% 891
2023
Q1 		$3.02M Buy
911,962
+420,310
+85% +$1.45M 0.01% 832
2022
Q4 		$1.91M Buy
491,652
+165,540
+51% +$511K 0.01% 926
2022
Q3 		$793K Buy
+326,112
New +$782K ﹤0.01% 1199
2020
Q1 		– Sell
-22,825
Closed -$91K – 2231
2019
Q4 		$91K Buy
+22,825
New +$99.5K ﹤0.01% 1685
2018
Q4 		– Sell
-309
Closed -$2K – 2186
2018
Q3 		$2K Buy
+309
New +$1.78K ﹤0.01% 2135

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes's ADMA Position: Q2 2026 in Review

Federated Hermes reduced its ADMA Biologics (ADMA) stake by 40% in Q2 2026, selling an estimated $6.26M and leaving 1,014,817 shares worth $8.49M. The position accounts for 0.01% of the portfolio, ranked #734.

Federated Hermes first reported a position in ADMA in Q3 2018 and has held it in 18 quarters since. The position peaked at $32.5M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Federated Hermes held 1,014,817 shares of ADMA Biologics worth $8.49M as of Q2 2026.
  • Federated Hermes sold 686,498 ADMA Biologics shares in Q2 2026, an estimated $6.26M.
  • ADMA Biologics made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #734 holding.
  • Federated Hermes first reported a position in ADMA Biologics in Q3 2018 and has held it in 18 quarters since.
  • Federated Hermes's ADMA Biologics position peaked at $32.5M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.